Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables: 2015-2017

Historic Notes Payables for Gyre Therapeutics (GYRE) over the last 3 years, with Dec 2017 value amounting to $5.1 million.

  • Gyre Therapeutics' Notes Payables fell 73.79% to $5.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.1 million, marking a year-over-year decrease of 73.79%. This contributed to the annual value of $5.1 million for FY2017, which is 73.79% down from last year.
  • Per Gyre Therapeutics' latest filing, its Notes Payables stood at $5.1 million for FY2017, which was down 73.79% from $19.4 million recorded in FY2016.
  • Over the past 5 years, Gyre Therapeutics' Notes Payables peaked at $33.7 million during FY2015, and registered a low of $5.1 million during FY2017.
  • For the 3-year period, Gyre Therapeutics' Notes Payables averaged around $19.4 million, with its median value being $19.4 million (2016).
  • Data for Gyre Therapeutics' Notes Payables shows a maximum YoY slumped of 73.79% (in 2017) over the last 5 years.
  • Yearly analysis of 3 years shows Gyre Therapeutics' Notes Payables stood at $33.7 million in 2015, then plummeted by 42.50% to $19.4 million in 2016, then plummeted by 73.79% to $5.1 million in 2017.